[Docetaxel (taxotere) in non-small-cell bronchial carcinoma].
BACKGROUND
Various new drugs with different mechanisms of action are presently under investigation for the field of solid tumors. The taxanes, Taxotere and Taxol, are among those drugs possessing a unique mechanism of action but showing pharmacological differences.


CONCLUSIONS
The results of several phase I and II studies of Taxotere in monotherapy as well as in combination schedules with chemotherapy and Radiotherapy show Taxotere to be active in non small cell lung cancer and build the basis for further evaluation in clinical trials.
Manegold
C
C
Thoraxklinik Heidelberg.
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015996:Survival Rate; D043823:Taxoids; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel